Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.

Criscitiello, C., Bagnardi, V., Viale, G., Disalvatore, D., Rotmensz, N., Esposito, A., et al. (2016). HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence. ANTICANCER RESEARCH, 36(7), 3537-3540.

HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence

BAGNARDI, VINCENZO
Secondo
;
2016

Abstract

Aim: The primary aim of the study was to assess the association between risk of recurrence and HER2 equivocal gene status through immunohistochemistry in patients with early breast cancer. Patients and Methods: We retrospectively analyzed clinical and pathological data of 455 consecutive patients with early breast cancer (BC) who were HER2+ and had a HER2/CEP17 ratio <2.0, who underwent surgery at the European Institute of Oncology after 2007. The role of HER2/CEP17 ratio on recurrencefree survival was assessed with univariate and multivariate Cox regression models. Results: We found no significant association between risk of recurrence and HER2 equivocal testing in patients with early breast cancer. In subgroup analysis, a significant interaction between HER2/CEP17 ratio and nodal involvement was observed (p=0.02). Conclusion: Patients with HER2 equivocal status have no significantly higher risk of recurrence.
Articolo in rivista - Articolo scientifico
Breast cancer; Equivocal HER2 status; HER2 amplification; Heterogeneity;
chronic rejection; graft failure; kidney transplantation; malignancy; nonmelanoma skin cancer; post-transplant lymphoprolipherative disorder
English
3537
3540
4
Criscitiello, C., Bagnardi, V., Viale, G., Disalvatore, D., Rotmensz, N., Esposito, A., et al. (2016). HER2 equivocal status in early breast cancer is not associated with higher risk of recurrence. ANTICANCER RESEARCH, 36(7), 3537-3540.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/136292
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
Social impact